Skip to content

Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients

Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01473459
Enrollment
40
Registered
2011-11-17
Start date
2012-04-30
Completion date
2013-01-31
Last updated
2012-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Obese, Polycystic Ovary Syndrome

Keywords

best fertility protocol, (BMI > 30), women, PCOS

Brief summary

The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF). These protocols carry less risk of ovarian hyperstimulation syndrome which these women may experience.

Detailed description

The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF). These protocols carry less risk of ovarian hyperstimulation syndrome which these women may experience.The patients in the IVM group will not be exposeD to gonadotropin treatment for controlled ovarian hyperstimulation. In the antagonist group we will use GnRH agonist to induce ovulation which may reduce the risk for ovarian hyperstimulation.

Interventions

PROCEDUREIVM (In Vitro Maturation) Treatment

There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.

PROCEDUREIVF (In Vitro Fertilization) Antagonist Protocol

The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI \> 30 * PCOS * Failure of COH treatment

Design outcomes

Primary

MeasureTime frame
Fertility resultsOne year

Countries

Israel

Contacts

Primary ContactTal Shavit, MD
tal.shavit@gmail.com972-50-6246712

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026